Patents by Inventor Steven M. Muskal

Steven M. Muskal has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20190277833
    Abstract: The present invention relates, in part, to treatment of various diseases and disorders such as GI disorders through modulation of F420-dependent enzymes including specific enzymes involved in methanogenesis.
    Type: Application
    Filed: May 12, 2017
    Publication date: September 12, 2019
    Inventors: Klaus GOTTLIEB, Michael KALEKO, Vincent J. WACHER, Steven M. MUSKAL
  • Publication number: 20020077754
    Abstract: Specialized apparatus and methods may be used for identifying, representing, and productively using high activity regions of chemical structure space. At least two representations of chemical structure space provide valuable information. A first representation has many dimensions representing members of a pharmacophore basis set and one or more additional dimensions representing defined chemical activity (e.g., pharmacological activity). A second representation has many fewer dimensions, each of which represents a principle component obtained by transforming the first representation via principal component analysis used on pharmacophore fingerprint/activity data for a collection of compounds. When the collection of compounds has the defined chemical activity, that activity will be reflected as a “high activity” region of chemical space in the second representation.
    Type: Application
    Filed: October 12, 1999
    Publication date: June 20, 2002
    Inventors: MALCOLM J. MCGREGOR, STEVEN M. MUSKAL
  • Publication number: 20020052694
    Abstract: Specialized apparatus and methods may be used for identifying, representing, and productively using high activity regions of chemical structure space. At least two representations of chemical structure space provide valuable information. A first representation has many dimensions representing members of a pharmacophore basis set and one or more additional dimensions representing defined chemical activity (e.g., pharmacological activity). A second representation has many fewer dimensions, each of which represents a principle component obtained by transforming the first representation via principal component analysis used on pharmacophore fingerprint/activity data for a collection of compounds. When the collection of compounds has the defined chemical activity, that activity will be reflected as a “high activity” region of chemical space in the second representation.
    Type: Application
    Filed: June 7, 2001
    Publication date: May 2, 2002
    Inventors: Malcolm J. McGregor, Steven M. Muskal